Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Mar 2019 |
  • Pages : 238 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Immune Checkpoint Inhibitors Market - Insights

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Introduction of novel immune checkpoint inhibitors with less side effects is driving global immune checkpoint inhibitors market growth

Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to better understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immune checkpoint inhibitors exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Manufactures are developing immune checkpoint inhibitors, which are tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Moreover, in April 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), who are not eligible for cisplatin chemotherapy, which is currently in the clinical phase 4.

The global immune checkpoint inhibitors market size was valued at US$ 10,543.8 million in 2017, and is expected to witness a robust CAGR of 11.8% over the forecast period (2018 – 2026).

 Figure No.1: Global Immune Checkpoint Inhibitors Market Share (%), by Region, 2018 and 2026

Immune Checkpoint Inhibitors  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2017)

Active research and development by leading players as well as small innovative organizations are expected to boost growth of the immune checkpoint inhibitors market

Immune checkpoint inhibitor is gaining significant traction as an efficient therapy for cancer treatment worldwide owing to less side effects, and targeted therapeutic effect. Therefore, various pharmaceuticals, biotech companies, universities, and cancer centers are focusing on investing in this segment. According to the Tufts Center for the Study of Drug Development (CSDD) report, 2016, currently, over 130 biotech and 20 pharma companies are developing immuno-oncology therapies, thereby fueling immune checkpoint inhibitors market growth in the forecast period. Also, according to the New York-based, Cancer Research Institute (CRI), 2017, currently 2,004 immuno-oncology agents including 940 in clinical stage and 1,064 in preclinical stage are under development. Leading players are actively investing in research and development in oncology treatment through various collaborations and individual research studies, owing to benefits associated with immune-oncology therapies. Advent of innovative immune-oncology therapies such as immune checkpoint inhibitors, have supported growth of the market. For instance, in 2016, AbbVie and the University of Texas MD Anderson Cancer Center entered into a three-year agreement for focusing on immune system’s complete potential to fight against cancer.

Figure No.2: Global Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis and Forecast and Y-o-Y Growth (%) (2018-2026)

             Immune Checkpoint Inhibitors  | Coherent Market Insights             

Source: Coherent Market Insights Analysis (2017)

Table No.1: Atezolizumab (Tecentriq) Years of Approval and Indications

Year of Approval Atezolizumab (Tecentriq) Indication
2016 Urothelial Carcinoma
2016 Specific Type of Metastatic Lung Cancer
2017 Initial Treatment for Certain People with Advanced Bladder Cancer
2018 Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
2019 Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Source: Company Annual Reports

However, high cost of immuno-oncology therapies, which is unaffordable to low and middle income population is restraining immune checkpoint inhibitors market growth. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer cost around US$ 2,250 for a vial of 50 mg.

Some of the major players operating in the immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.

Immune checkpoint inhibitor products come under biologic therapeutic products. Biologic manufacturers require similar kind of approvals such as drugs from the U.S. Food & Drug Administration prior to bringing the product into market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Initiatives undertaken by the governments include funding is expected to drive growth of the immune checkpoint inhibitors market. For instance, in 2017, National Institutes of Health partnered with 11 leading biopharmaceutical companies such as AbbVie and Amgen, Inc. to accelerate development of new immunotherapies.

Market Dynamics

Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of Global Immune Checkpoint Inhibitors Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the Global Immune Checkpoint Inhibitors Market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
  • The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Global Immune Checkpoint Inhibitors Market

Detailed Segmentation:

  • Global Immune Checkpoint Inhibitors Market, By Drug Class:
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  • Global Immune Checkpoint Inhibitors Market, By Cancer Type:
    • Lung Cancer
    • Head & Neck Cancer
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Blood Cancer (Lymphoma)
    • Bladder Cancer (Urothelial Carcinoma)
    • Renal/Kidney Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immune Checkpoint Inhibitors Market, By Geography:
    • North America
      • By Drug Class
        • Programmed Death Receptor-1 (PD-1) Inhibitors
          • Pembrolizumab (Keytruda)
          • Nivolumab (Opdivo)
          • Cemiplimab (Libtayo)
          • Others
        • Programmed Death-Ligand 1 (PD-L1) Inhibitors
          • Atezolizumab (Tecentriq)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
        • CTL-4 Checkpoint Inhibitor
          • Ipilimumab (Yervoy)
        • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
        • Lymphocyte-Activation Gene 3 Inhibitors        
      • By Cancer Type:
        • Lung Cancer
        • Head & Neck Cancer
        • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
        • Blood Cancer (Lymphoma)
        • Bladder Cancer (Urothelial Carcinoma)
        • Renal/Kidney Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class
        • Programmed Death Receptor-1 (PD-1) Inhibitors
          • Pembrolizumab (Keytruda)
          • Nivolumab (Opdivo)
          • Cemiplimab (Libtayo)
          • Others
        • Programmed Death-Ligand 1 (PD-L1) Inhibitors
          • Atezolizumab (Tecentriq)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
        • CTL-4 Checkpoint Inhibitor
          • Ipilimumab (Yervoy)
        • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
        • Lymphocyte-Activation Gene 3 Inhibitors        
      • By Cancer Type:
        • Lung Cancer
        • Head & Neck Cancer
        • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
        • Blood Cancer (Lymphoma)
        • Bladder Cancer (Urothelial Carcinoma)
        • Renal/Kidney Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Russia
        • Spain
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Programmed Death Receptor-1 (PD-1) Inhibitors
          • Pembrolizumab (Keytruda)
          • Nivolumab (Opdivo)
          • Cemiplimab (Libtayo)
          • Others
        • Programmed Death-Ligand 1 (PD-L1) Inhibitors
          • Atezolizumab (Tecentriq)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
        • CTL-4 Checkpoint Inhibitor
          • Ipilimumab (Yervoy)
        • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
        • Lymphocyte-Activation Gene 3 Inhibitors        
      • By Cancer Type:
        • Lung Cancer
        • Head & Neck Cancer
        • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
        • Blood Cancer (Lymphoma)
        • Bladder Cancer (Urothelial Carcinoma)
        • Renal/Kidney Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • By Drug Class
        • Programmed Death Receptor-1 (PD-1) Inhibitors
          • Pembrolizumab (Keytruda)
          • Nivolumab (Opdivo)
          • Cemiplimab (Libtayo)
          • Others
        • Programmed Death-Ligand 1 (PD-L1) Inhibitors
          • Atezolizumab (Tecentriq)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
        • CTL-4 Checkpoint Inhibitor
          • Ipilimumab (Yervoy)
        • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
        • Lymphocyte-Activation Gene 3 Inhibitors        
      • By Cancer Type:
        • Lung Cancer
        • Head & Neck Cancer
        • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
        • Blood Cancer (Lymphoma)
        • Bladder Cancer (Urothelial Carcinoma)
        • Renal/Kidney Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of LATAM
    • Middle East
      • By Drug Class
        • Programmed Death Receptor-1 (PD-1) Inhibitors
          • Pembrolizumab (Keytruda)
          • Nivolumab (Opdivo)
          • Cemiplimab (Libtayo)
          • Others
        • Programmed Death-Ligand 1 (PD-L1) Inhibitors
          • Atezolizumab (Tecentriq)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
        • CTL-4 Checkpoint Inhibitor
          • Ipilimumab (Yervoy)
        • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
        • Lymphocyte-Activation Gene 3 Inhibitors        
      • By Cancer Type:
        • Lung Cancer
        • Head & Neck Cancer
        • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
        • Blood Cancer (Lymphoma)
        • Bladder Cancer (Urothelial Carcinoma)
        • Renal/Kidney Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Programmed Death Receptor-1 (PD-1) Inhibitors
          • Pembrolizumab (Keytruda)
          • Nivolumab (Opdivo)
          • Cemiplimab (Libtayo)
          • Others
        • Programmed Death-Ligand 1 (PD-L1) Inhibitors
          • Atezolizumab (Tecentriq)
          • Avelumab (Bavencio)
          • Durvalumab (Imfinzi)
        • CTL-4 Checkpoint Inhibitor
          • Ipilimumab (Yervoy)
        • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
        • Lymphocyte-Activation Gene 3 Inhibitors        
      • By Cancer Type:
        • Lung Cancer
        • Head & Neck Cancer
        • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
        • Blood Cancer (Lymphoma)
        • Bladder Cancer (Urothelial Carcinoma)
        • Renal/Kidney Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Collaborations & Partnerships
    • Major FDA Approvals & Product Launch Scenario
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Porter’s Five Forces Analysis
  4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  5. Global Immune Checkpoint Inhibitors Market, By Application, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Head & Neck Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Blood Cancer (Lymphoma)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Bladder Cancer (Urothelial Carcinoma)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Renal/Kidney Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
  6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
  7. Global Immune Checkpoint Inhibitors Market, By Regions, 2018–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of LATAM
    • Middle East
      • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • ImmunOs Therapeutics AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Immutep Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • NewLink Genetics Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Ono Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 46 market data tables and 41 figures on "Immune Checkpoint Inhibitors Market - Global forecast to 2026”

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.